Who are Camrelizumab+Apatinib+Eribulin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/camrelizumab-apatinib-eribulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Camrelizumab+Apatinib+Eribulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab+Apatinib+Eribulin (Camrelizumab+Apatinib+Eribulin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor + tyrosine kinase inhibitor + microtubule inhibitor combination. Area: Oncology.

phase 3 PD-1 inhibitor + tyrosine kinase inhibitor + microtubule inhibitor combination PD-1 (camrelizumab), VEGFR-2 (apatinib), microtubule dynamics (eribulin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Camrelizumab+Apatinib+Eribulin (Camrelizumab+Apatinib+Eribulin) — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. This combination therapy enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while simultaneously inhibiting angiogenesis and disrupting microtubule dynamics to suppress tumor growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Camrelizumab+Apatinib+Eribulin TARGET	Camrelizumab+Apatinib+Eribulin	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	PD-1 inhibitor + tyrosine kinase inhibitor + microtubule inhibitor combination	PD-1 (camrelizumab), VEGFR-2 (apatinib), microtubule dynamics (eribulin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor + tyrosine kinase inhibitor + microtubule inhibitor combination class)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Camrelizumab+Apatinib+Eribulin — Competitive Intelligence Brief. https://druglandscape.com/ci/camrelizumab-apatinib-eribulin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab